Physician profile
Christa Shilling
NPI 1306925623
$3,234.49
in general payments reported to CMS, 2019-2025
24 companies · $533 in 2025
The $533 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $298 · 2021: $519 · 2022: $323 · 2023: $508 · 2024: $790 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $364.23 | 2019-2025 | Penmenvy, Bexsero, Shingrix |
| Tris Pharma INC | $360.56 | 2019-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $299.11 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $285.69 | 2022-2025 | Azstarys |
| Pfizer INC. | $283.44 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $272.72 | 2020-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Ironshore Pharmaceuticals INC. | $246.93 | 2019-2024 | |
| Adlon Therapeutics L.P. | $166.24 | 2020-2021 | |
| Alk-Abello, INC | $149.59 | 2024-2025 | Ragwitek, Grastek, Odactra |
| Kaleo, INC. | $127.13 | 2019-2023 | Auvi-Q |
| Sanofi Pasteur INC. | $125.18 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.72 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $82.85 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $79.07 | 2019-2024 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $74.20 | 2022-2024 | Flumist Quadrivalent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $71.74 | 2024-2025 | Biofire Spotfire Control Station, Biofire Spotfire Respiratory (R) Panel |
| Lnhc, INC | $33.25 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $22.28 | 2024 | Ycanth |
| Ultragenyx Pharmaceutical INC. | $22.26 | 2025 | Dojolvi |
| Vertical Pharmaceuticals, LLC | $19.11 | 2025 | Relexxii |
| Alexion Pharmaceuticals, INC. | $18.52 | 2020 | |
| Biomarin Pharmaceutical INC. | $17.79 | 2023 | Voxzogo 1.2mg |
| Seqirus USA INC | $13.97 | 2022 | |
| Shire North American Group INC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christa Shilling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.